The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $1.37

Today's change+0.01 +0.74%
Updated January 20 4:00 PM EST. Delayed by at least 15 minutes.
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $1.37

Today's change+0.01 +0.74%
Updated January 20 4:00 PM EST. Delayed by at least 15 minutes.

Arena Pharmaceuticals Inc up (U.S.)$0.01

Arena Pharmaceuticals Inc closed up Friday by (U.S.)$0.01 or 0.74% to (U.S.)$1.37. Over the last five days, shares have lost 3.52% and sit 3.79% above their 52-week low. This security has underperformed the S&P 500 by 40.12% during the last year.

Key company metrics

  • Open(U.S.) $1.35
  • Previous close(U.S.) $1.36
  • High(U.S.) $1.40
  • Low(U.S.) $1.34
  • Bid / Ask(U.S.) $1.34 / (U.S.) $1.45
  • YTD % change-3.52%
  • Volume1,868,378
  • Average volume (10-day)2,035,020
  • Average volume (1-month)1,788,040
  • Average volume (3-month)1,754,068
  • 52-week range(U.S.) $1.32 to (U.S.) $2.16
  • Beta-0.70
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.38
Updated January 20 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-197.77%

Although this company's net profit margin is negative, it is above the industry average and implies that Arena Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.90%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue1910108
Total other revenue--------
Total revenue1910108
Gross profit16765
Total cost of revenue3343
Total operating expense29362937
Selling / general / administrative99710
Research & development17191920
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)05--4
Other operating expenses, total--------
Operating income-10-26-19-29
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-12-27-22-30
Income after tax-12-27-22-30
Income tax, total--------
Net income-12-27-22-30
Total adjustments to net income--------
Net income before extra. items-12-27-22-30
Minority interest0------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-12-27-22-30
Inc. avail. to common incl. extra. items-12-27-22-30
Diluted net income-12-27-22-30
Dilution adjustment000--
Diluted weighted average shares243243243243
Diluted EPS excluding extraordinary itemsvalue per share-0.05-0.11-0.09-0.13
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.05-0.09-0.09-0.11